Takeda Pharmaceutical Co. Ltd. and Takeda Global Research & Development Center, Inc., received notification that the FDA has agreed to the study design for the cardiovascular (CV) outcomes trial EXAMINE for alogliptin, a selective DPP-IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. The trial will be a multicenter, randomized, double-blind, placebo-controlled study to evaluate cardiovascular outcomes following treatment with aloglip...